Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors
/PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the...
Stay updated with breaking news from Pitango Venture. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the...
/PRNewswire/ -- Protai, an AI-powered drug discovery startup, today announced its emergence from stealth, along with an $8 million seed financing round co-led...
The company has developed an end-to-end AI-based platform that can map the course of a disease on the protein level
Published: Jan 07, 2021 WALTHAM, Mass.--(BUSINESS WIRE)-- TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the appointment of Brian M. Silver, J.D., to its Board of Directors. Mr. Silver is Chief Financial Officer and Head of Corporate Development at Freeline Therapeutics Holdings plc, a clinical-stage systemic gene therapy company. Prior to joining Freeline in 2018, Mr. Silver was Partner and Head of Biotechnology in the healthcare practice at Perella Weinberg Partners, a leading i...